Clinical Trial Update: Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated ranibizumab injections for macular telangiectasia with neovascularization, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Neovascularization | Phase 1 | Status: COMPLETED